Page 5,117«..1020..5,1165,1175,1185,119..5,1305,140..»

American Health Journal PBS Special Laminine Stem Cell Therapy Full Version – Video

Posted: Published on June 20th, 2013

American Health Journal PBS Special Laminine Stem Cell Therapy Full Version http://www.LaminiNHealth.com/dc/ Doctors are interviewed about Fibroblast Growth Factor, Laminin, Cortisol, Serotonin Do-It-Yourself Stem Cell Therapy - La... By: David Dolores … Continue reading →

Comments Off on American Health Journal PBS Special Laminine Stem Cell Therapy Full Version – Video

Two Studies Evaluating the Combination of REVLIMID® and rituximab in Non-Hodgkin’s Lymphomas Presented at …

Posted: Published on June 20th, 2013

BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation (CELG), today announced that results from two studies evaluating the combination of REVLIMID (lenalidomide) and rituximab in various non-Hodgkins lymphomas were presented at the 12th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. The increasing volume of clinical evidence evaluating combinations utilizing REVLIMID plus rituximab provide us powerful insight into the potential of antibody-dependent cellular cytotoxicity in lymphomas, and the potential of these novel combinations in patients in subtypes with a poor prognosis, said Jean-Pierre Bizzari, M.D., Executive Vice President, Hematology and Oncology for Celgene Corporation. We look forward with great interest to further data from the studies presented at this years ICML conference. Lenalidomide plus rituximab in patients with previously untreated follicular lymphoma In this preliminary report from a phase II study, conducted by the Alliance for Clinical Trials in Oncology, and presented by Peter Martin, M.D., Assistant Professor of Medicine at Weill Cornell Medical College, patients with untreated follicular lymphoma, including those with grade 1-3a, stage 3-4 or bulky stage 2 and FLIPI 0-2 disease, were given lenalidomide (20mg/day on days 1-21 of each 28-day cycle) for 12 cycles and rituximab (four weekly doses of … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Two Studies Evaluating the Combination of REVLIMID® and rituximab in Non-Hodgkin’s Lymphomas Presented at …

Big leukemia breakthrough?

Posted: Published on June 20th, 2013

Ibrutinib, seen here, is being considered a breakthrough drug that might one day replace chemotherapy. STORY HIGHLIGHTS (TIME.com) -- It's called ibrutinib, and it's a potential breakthrough in treating chronic lymphocytic leukemia (CLL) that could leave patients with fewer side effects than chemotherapy. In research published in the New England Journal of Medicine (NEJM), scientists report that the experimental drug, which differs from broadly acting chemotherapy agents by specifically targeting certain cancer-causing processes, significantly prolongs the life of patients. Ibrutinib is currently being tested on tumors that target the body's immune system, such as CLL and mantle cell lymphoma (MCL). CLL is the second most common form of leukemia among adults in the U.S., and about 15,000 Americans, most of whom are elderly, are diagnosed with the blood and bone marrow cancer every year. The drug is the first to bind to and block the activity of a protein known as Bruton's tyrosine kinase (BTK), which plays an important role in helping immune cell tumors, which develop from abnormally growing blood stem cells, to grow. Once ibrutinib binds to the immune system's B-cells, it prevents tumors growing in these cells from signaling for the nutrients they need to grow and … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Big leukemia breakthrough?

Diabetics may soon need just 1 shot a year

Posted: Published on June 20th, 2013

PTI Jun 18, 2013, 06.08AM IST LONDON: Scientists have made a stem cell breakthrough that could make it possible to treat diabetics with an annual insulin jab, eliminating the need for painful daily injections. The technique involves engineering blood stem cells into insulin-secreting cells. Experts at London's Imperial College, led by Nagy Habib , and scientists at Hammersmith Hospital are now planning human trials of the new treatment after success in laboratory studies, the 'Daily Express' reported. "This is a fantastic breakthrough that we hope will end the burden of daily jabs for diabetics," said Dr Paul Mintz, a leading stem cell researcher at Imperial College, who is part of the team pioneering the research. "The beauty of this treatment is that we manipulate the patient's own stem cells, avoiding the complication of giving them something foreign which their body will reject ," he said. In diabetes, the pancreas fails to make insulin which crucially controls blood sugar levels or it doesn't make enough. Read more here: Diabetics may soon need just 1 shot a year … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Diabetics may soon need just 1 shot a year

Stem cell treatment rapidly gains reputation as means to cure illnesses – Video

Posted: Published on June 20th, 2013

Stem cell treatment rapidly gains reputation as means to cure illnesses News@1 Junior Edition - Stem cell treatment rapidly gains reputation as means to cure illnesses (Reported by EO Galvez) [June 16, 2013] For more news, visit:... By: PTV PH … Continue reading →

Comments Off on Stem cell treatment rapidly gains reputation as means to cure illnesses – Video

Cell Therapie® Success Story | Anna – Stem Cell Treatment for Knee

Posted: Published on June 20th, 2013

Cell Therapie Success Story | Anna - Stem Cell Treatment for Knee Back Pain http://www.celltherapieforme.com. Testimonial from Anna who suffered from a fractured fibula and back pain from an accident. After consulting numerous doctor... By: CellTherapie … Continue reading →

Comments Off on Cell Therapie® Success Story | Anna – Stem Cell Treatment for Knee

Fibrosis treatment research – Video

Posted: Published on June 20th, 2013

Fibrosis treatment research I created this video with the YouTube Slideshow Creator (http://www.youtube.com/upload) By: Bharat Gajjar … Continue reading →

Comments Off on Fibrosis treatment research – Video

Stearns family waits for outcome of stem cell transplant

Posted: Published on June 20th, 2013

BLUE MOUND The stress of leukemia treatment weighs heavily not only on Brynn Stearns, but also on her two children. Before Stearns had a stem cell transplant at Loyola University in Chicago on June 11, her doctors warned of what was likely to happen to her body over the next four months. She received massive doses of chemotherapy drugs for several days before the transplant to effectively kill her immune system. She is experiencing nausea, diarrhea, mouth sores and hair loss. Medications to reduce those side-effects have their own side-effects such as anxiety, drowsiness, muscle tightness and shakiness. Im just nervous of the outcome, Stearns said. The chemo and how youre going to be sick. Now, as the family waits, the effect on Kaydence, 6, and Kolby, 5, is apparent. When the topic turns to their mothers future, the two otherwise active children become quiet and stare blankly. It plays on the kids, Stearns mother Nancy Piper said. When we talk about it, theyre quiet. As a single mother, the first concern for Stearns is her children. Theyre the whole reason why Im doing this, she said. Stearns and her family began her medical journey almost three years ago. In … Continue reading →

Comments Off on Stearns family waits for outcome of stem cell transplant

Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® …

Posted: Published on June 20th, 2013

LUGANO, Switzerland--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (SGEN) today announced data from a post-hoc analysis examining progression-free survival (PFS) following treatment with ADCETRIS (brentuximab vedotin) versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma (HL) post-autologous stem cell transplant (ASCT) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma (ICML) being held June 1922, 2013 in Lugano, Switzerland. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and sALCL. The post-hoc analysis compared investigator assessed PFS following ADCETRIS single-agent treatment to the last prior systemic therapy in patients taking part in two pivotal Phase 2 studies. The post-hoc analysis was conducted in patients with relapsed or refractory HL post-ASCT or relapsed or refractory sALCL in the intent-to-treat (ITT) population. It also included prior systemic treatment histories and post-ADCETRIS stem cell transplant experience for each patient in the ITT populations. These encouraging data suggest that ADCETRIS may delay disease progression compared to prior therapies used in this heavily pretreated patient population, said John Radford, M.D., Professor of Medical Oncology, University … Continue reading →

Comments Off on Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® …

NIH to fund collaborations with industry to identify new uses for existing compounds

Posted: Published on June 19th, 2013

Public release date: 18-Jun-2013 [ | E-mail | Share ] Contact: NCATS Office of Communications ncatsinfo@mail.nih.gov 301-435-0888 NIH/National Center for Advancing Translational Sciences (NCATS) The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia. The collaborative pilot initiative, called Discovering New Therapeutic Uses for Existing Molecules, is led by the National Center for Advancing Translational Sciences (NCATS) and funded by the NIH Common Fund. The process of developing a new therapeutic is long and difficult. The average length of time from target discovery to approval of a new drug is more than 13 years, and the failure rate exceeds 95 percent. This failure rate means, however, that many existing partially developed compounds could be advanced to clinical trials more quickly than starting from scratch. "With thousands of diseases remaining untreatable, there is a sense of urgency to accelerate the pace at which discoveries are transformed into therapies for patients," said Health and Human Services Secretary Kathleen Sebelius. "This program helps forge partnerships between the pharmaceutical industry and the biomedical research … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on NIH to fund collaborations with industry to identify new uses for existing compounds

Page 5,117«..1020..5,1165,1175,1185,119..5,1305,140..»